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Abstract
Background: Nontuberculous mycobacteria (NTM) are pathogens that commonly affect the paediatric population
and its most frequent manifestation is a cervicofacial lymphadenopathy. With the improvement of technologies,
new species have been recently identified.
Case presentation: We report the first case of NMT lymphadenitis in a child caused by Mycobacterium marseillense,
a newly described species belonging to Mycobacterium avium complex.
Conclusions: Improving the identification of these newly discovered mycobacteria, further information will be available
about their clinical involvement and their best treatment.
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Background
Nontuberculous mycobacteria (NTM) are pathogens
causing different patterns of diseases, ranging from an
asymptomatic colonization to a widespread dissemin-
ation, depending on the host immune competence [1].
NMT can be found in soil, water, milk, eggs, vegetables
and animals. In immunocompetent children, they usually
cause an unilateral, painless, progressive lymphadenop-
athy that lacks constitutional symptoms. Submandibular
and cervical lymph node stations are mainly involved,
while the incidence of preauricolar, inguinal and axillary
area affection is lower [2].
Cervicofacial NTM lymphadenitis affects mainly
children below 4 years of age, while it is rarely diagnosed
in adolescents. The estimated incidence of NTM disease
is of 0.6 to 1.6 cases per 100,000 children per year and it
increases during spring and late winter [2].
More than 150 species of NTM have been recognized,
but less than 20 species have been identified in human
infections [3]. Members of Mycobacterium avium complex
(MAC) are the causative agents of more than 75% of cases
of NTM lymphadenitis, followed by Mycobacterium
haemophilum (6%) [4].
Mycobacterium marseillense has recently been de-
scribed as a new species belonging to the MAC complex
[5]. We report on the first case of NMT lymphadenitis
caused by Mycobacterium marseillense in a child.
Case presentation
We evaluated a 4 years old girl, previously healthy, with
no relevant family medical history. She was conducted
to our clinic because of a submandibular lymphadenitis.
A month before, during a 3 days fever period, a painful
submandibular swelling was noted. Neck ultrasound
(US) showed a 2-cm diameter lymphadenopathy with a
conserved structure. Therapy with ibuprofen was then
suggested. Because of symptoms persistence, a control
US was repeated after 5 days. The lymph node was en-
larged and presented a subverted structure, with hypoe-
chogenic areas and an absent roundness index (Fig. 1).
Therapy with co-amoxiclav was immediately started at a
dosage of 80 mg/kg/day for 6 days. Blood tests showed a
slight increase in C-reactive protein values (53 mg/L;
normal value <50 mg/L) and erythrocyte sedimentation
rate (31 mm/h); serology for Cytomegalovirus confirmed
a previous infection, while IgM for Epstein Barr Virus
(EBV) were positive. Blood smear was normal. Tuberculin
skin test resulted positive (10 mm infiltration diameter).
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QuantiFERON-TB Gold In-tube test and chest X-ray
resulted negative.
Neck US performed after 20 days was unchanged.
Therefore the girl was referred to our infectious disease
unit for further investigations. At physical examination,
a fixed right submandibular lymphadenopathy, with an
elastic consistency, painless and with no superficial skin
alterations was detected. No other significant clinical
features were described. Blood tests showed no
alteration in blood count, inflammatory markers, liver
function, lactic dehydrogenase, coagulation. Francisella
tularensis and Toxoplasma gondii serology were nega-
tive. EBV serology showed evidence of a past infection.
In the suspicion of an NTM lymphadenitis, antimicro-
bial therapy with clarithromycin (15 mg/kg/die), and
rifampicin (20 mg/kg per day) was started. A magnetic
resonance imaging showed a confluent lymphonodal
pack inside the inferior pole of the right parotid gland
(4 × 4.2 × 2.9 cm) that was enhanced after contrast
medium infusion. The enhancement involved also the
whole parotid gland parenchyma and the ipsilateral
sternocleidomastoid muscle.
Due to sudden enlargement of swelling, exeresis of the
lymph node was performed. Bacterioscopic exam
showed a positivity for acid-fast bacilli, and the histo-
logical examination evidenced a granulomatous inflam-
mation. Culture from the biopsy grew a M. marseillense
strain, identified using a commercial kit (Hain Genotype
Mycobacteria CM, Hain Lifescience, Germany) and
sequencing the spacer region interposed between 16S
and 23S rRNA genes, as described previously [6].
Because of a slow healing up of the surgical scar, etham-
butol (25 mg/kg/die) was added to the previous therapy.
Antimicrobial treatment was well tolerated by the
patient and no adverse effect were reported. Blood exams
and clinical assessment were periodically performed in
order to evaluate potential drug-induced toxicity. Therapy
was finally stopped 2 months after surgery.
Periodical blood tests and neck US were performed.
At 10 months follow up visit, no relapse was found and
the surgical scar was completely healed.
Discussion and conclusion
To the best of our knowledge, this is the first reported
case of lymphadenitis due to M. marseillense in a child,
moreover immunocompetent. NTM infection should
always be considered in the differential diagnosis of
chronic lymphadenopathies, especially in children below
4 years of age. MAC is the most common cause of NTM
lymphadenitis, with M. avium being the species most
frequently isolated. However, mycobacterial taxonomy is
often a challenge for microbiologists, because of the new
species that are continuously described due to the appli-
cation of molecular techniques [3].
M. marseillense was firstly described in 2009. It is a
slowly growing, small, acid-fast bacillus, belonging to the
MAC complex, showing the closest similarity with
Mycobacterium chimaera [5].
Clinical features of M. marseillense infections are not
yet clearly known due to the extreme rarity of these con-
ditions. Up to now, only two cases of pulmonary infec-
tion and two cases of isolation in the sputum of patients
with cystic fibrosis have been described [7]. One report
was about a 56 years old woman with systemic lupus
erythematosus who presented a story of cough and
purulent sputum with chest consolidation of the right
middle lobe at computed tomography (CT) scan,
unresponsive to multiple courses of antibiotics. After
Fig. 1 Preoperative ultrasound of patient’s lymph node
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bronchoscopy, M. marselleinse was isolated in broncho-
alveolar lavage [8]. The other report was about a 65 years
old immunocompetent man who presented at chest
radiographs a diffuse nodular opacity and bronchial
thickening, confirmed by high-resolution CT. On bron-
choalveolar lavage, a nontuberculous Mycobacterium
strain was isolated by culture and preliminarily identified
as M. intracellulare. Rifampin, isoniazid and amikacin
were initially prescribed, with clinical improvement. In
the subsequent 4 years, the patient presented intermit-
tently positive culture despite the various therapeutic
cycles. The last drug regimen was with ethambutol,
rifampin and azithromycin. Anyway, cough and sputum
production persisted despite negative microbiological
test results. Moreover, radiological follow up evidenced a
progressive pulmonary involvement [9].
As no other cases of lymphadenopathy due to M.
marseillense were described, no specific indications for
the treatment of this kind of infection were present in
the literature. Excision was performed as indicated in
NTM lymphadenitis and allowed the identification of
the germ. Therapy for NTM infections with macrolide
and rifampin was given as suggested by American Thoracic
Society and the Infectious Diseases Society of America
guidelines [10], and ethambutol was later added due to
delay in the healing of the surgical scar. Clinical and
radiological follow up showed a decrease of lymph node
dimension with an almost complete recovery at 6 months.
M. marseillense role in lymphadenitis could be under-
estimated given the similarities to M. intracellulare.
Further studies are needed to understand the clinical
involvement of these newly discovered mycobacteria in
NTM lymphadenitis and their best treatment.
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